DUBLIN--(BUSINESS WIRE)--The "United States Insulin Pen Market Size, Share, Opportunity, Analysis, Growth Potential & Demand Forecast 2017 - 2022" report has been added to Research and Markets' offering.
The report provides an in-depth analysis of overall diabetes population and insulin users. It provides essential insights into insulin pen users with more focused-on reusable and prefilled insulin pen users. Market outlook in value terms has been analysed based on current and potential trends and the market is estimated from 2017 to 2022. It also covers reimbursement pattern and offers a clear view of the regulatory landscape. The report also explores detailed description of growth drivers and inhibitors of the United States Insulin Pen Market.
Market growth can be attributed to factors such as diabetes patient population, user-friendly design, help avoid over/under-dosing of insulin, rising market demand for human insulin analogs and technological advancements in the field of insulin pen devices. However, low patient awareness, lack of device education and training among physicians and perception of the higher cost is expected to hamper growth of the market during forecast period.
The report concludes with the profiles of major players in the Insulin Pen Market such as Novo Nordisk, Eli Lilly, Sanofi, Owen Mumford.
Key Topics Covered:
1. Executive Summary
2. United States Diabetes Population & Insulin Users Analysis (2011 - 2022)
3. United States - Insulin Pen Users Trend & Analysis (2011 - 2022)
4. United States - Insulin Pen Market Trend & Analysis (2011 - 2022)
5. Key Drivers and Inhibitors of the United States Insulin Pen Market
6. United States Insulin Pen Market: Reimbursement & Regulation System
7. Key Companies Analysis
For more information about this report visit https://www.researchandmarkets.com/research/jcqzhh/united_states